Citations

Clear

23 citation(s) found for "Serrano, Jose".

Evaluation of Chronic Pancreatitis Prognosis Score in an American Cohort
Conwell, Darwin L. , Hart, Phil A. , Li, Shuang , Stello, Kimberly, Fogel, Evan L. , Fisher, William E., Forsmark, Christopher E., Park, Walter G. , Topazian, Mark , Vege, Santhi Swaroop , Yadav, Dhiraj , Saloman, Jami L. , Saloman, Jami L , Park, Soo Kyoung , Pandol, Stephen J. , Serrano, Jose, Van Den Eeden, Stephen K , Liang, Li

Mayo Clinic

Clinical and Translational Gastroenterology | August 13, 2024 | Volume: 15 | Issue: 11 | Pages: e00758

10.14309/ctg.0000000000000758 | PMID 39137098 Get It

INTRODUCTION: Chronic Pancreatitis Prognosis Score (COPPS) was developed to discriminate disease severity and predict risk for future hospitalizations. In this cohort study, we evaluated if COPPS predicts the likelihood of hospitalization(s) in an American cohort. METHODS: The Chronic Pancreatitis, Diabetes, and Pancreatic Cancer consortium provided data and serum from subjects with chronic pancreatitis (N = 279). COPPS was calculated with baseline data and stratified by severity (low, moderate, and high). Primary endpoints included number and duration of hospitalizations during 12-month follow-up. RESULTS: The mean ± SD COPPS was 8.4 ± 1.6. COPPS correlated with all primary outcomes: hospitalizations for any reason (number: r = 0.15, P = 0.01; duration: r = 0.16, P = 0.01) and pancreas-related hospitalizations (number: r = 0.15, P = 0.02; duration: r = 0.13, P = 0.04). The severity distribution was 13.3% low, 66.0% moderate, and 20.8% high. 37.6% of subjects had ≥1 hospitalization(s) for any reason; 32.2% had ≥1 pancreas-related hospitalizations. All primary outcomes were significantly different between severity groups: hospitalizations for any reason (number, P = 0.004; duration, P = 0.007) and pancreas-related hospitalizations (number, P = 0.02; duration, P = 0.04). The prevalence of continued drinking at follow-up ( P = 0.04) was higher in the low and moderate groups. The prevalence of anxiety at enrollment ( P = 0.02) and follow-up ( P < 0.05) was higher in the moderate and high groups. DISCUSSION: Statistically, COPPS significantly correlated with hospitalization outcomes, but the correlations were weaker than in previous studies, which may be related to the outpatient nature of the PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies cohort and lower prevalence of high severity disease. Studies in other prospective cohorts are needed to understand the full utility of COPPS as a potential tool for clinical risk assessment and intervention.
Systemic Neutrophil Gelatinase-Associated Lipocalin Alterations in Chronic Pancreatitis: A Multicenter, Cross-Sectional Study
Torok, Molly, Pfau, Timothy, Mace, Thomas A. , Cole, Rachel M. , Hart, Phil A. , Krishna, Somashekar G. , Lara, Luis F. , Ramsey, Mitchell L. , Fogel, Evan L. , Forsmark, Chris E. , Li, Liang , Park, Walter G. , Vege, Santhi Swaroop , Yadav, Dhiraj , Conwell, Darwin L. , Cruz‐Monserrate, Zobeida , Krishna, Somashekar G , Gumpper, Kristyn , Chasser, Kaylin M. , Pita-Grisanti, Valentina , Belury, Martha Ann , Culp, Stacey , Fisher, William P. , Pandol, Stephen J. , Serrano, José , Van Den Eeden, Stephen K

Mayo Clinic

Clinical and Translational Gastroenterology | January 29, 2024 | Volume: 15 | Issue: 4 | Pages: e00686

10.14309/ctg.0000000000000686 | PMID 38284831 Get It

INTRODUCTION: Chronic pancreatitis (CP) is a progressive fibroinflammatory disorder lacking therapies and biomarkers. Neutrophil gelatinase-associated lipocalin (NGAL) is a proinflammatory cytokine elevated during inflammation that binds fatty acids (FAs) such as linoleic acid. We hypothesized that systemic NGAL could serve as a biomarker for CP and, with FAs, provide insights into inflammatory and metabolic alterations. METHODS: NGAL was measured by immunoassay, and FA composition was measured by gas chromatography in plasma (n = 171) from a multicenter study, including controls (n = 50), acute and recurrent acute pancreatitis (AP/RAP) (n = 71), and CP (n = 50). Peripheral blood mononuclear cells (PBMCs) from controls (n = 16), AP/RAP (n = 17), and CP (n = 15) were measured by cytometry by time-of-flight. RESULTS: Plasma NGAL was elevated in subjects with CP compared with controls (area under the curve [AUC] = 0.777) or AP/RAP (AUC = 0.754) in univariate and multivariate analyses with sex, age, body mass index, and smoking (control AUC = 0.874; AP/RAP AUC = 0.819). NGAL was elevated in CP and diabetes compared with CP without diabetes ( P < 0.001). NGAL + PBMC populations distinguished CP from controls (AUC = 0.950) or AP/RAP (AUC = 0.941). Linoleic acid was lower, whereas dihomo-γ-linolenic and adrenic acids were elevated in CP ( P < 0.05). Linoleic acid was elevated in CP with diabetes compared with CP subjects without diabetes ( P = 0.0471). DISCUSSION: Elevated plasma NGAL and differences in NGAL + PBMCs indicate an immune response shift that may serve as biomarkers of CP. The potential interaction of FAs and NGAL levels provide insights into the metabolic pathophysiology and improve diagnostic classification of CP.
Circulating immune signatures across clinical stages of chronic pancreatitis: a pilot study
Hagn-Meincke, Rasmus , Hart, Phil A. , Andersen, Dana K. , Vege, Santhi Swaroop , Fogel, Evan L. , Topazian, Mark , Conwell, Darwin L. , Li, Liang , Drewes, Asbjørn Mohr , Forsmark, Chris E. , Fisher, William E., Yadav, Dhiraj , Olesen, Søren Schou , Park, Walter G. , Vege, Santhi S, Serrano, José , Bellin, Melena D. , Van Den Eeden, Stephen K , Pandol, Stephen J.

Mayo Clinic

European Journal of Gastroenterology & Hepatology | December 4, 2023 | Volume: 36 | Issue: 2 | Pages: 177-183

10.1097/meg.0000000000002691 | PMID 38047728 Get It

Objective This pilot study seeks to identify serum immune signatures across clinical stages of patients with chronic pancreatitis (CP). Methods We performed a cross-sectional analysis of prospectively collected serum samples from the PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translation StuDies-study. CP subjects were categorised into three clinical stages based on the presence/absence of metabolic complications: (1) CP with no diabetes and exocrine pancreatic dysfunction (EPD), (2) CP with either diabetes or EPD, and (3) CP with diabetes and EPD. Blinded samples were analysed using an 80-plex Luminex assay of cytokines/chemokines/adhesion molecules. Group and pairwise comparisons were performed to characterise immune signatures across CP subgroups. Results A total of 135 CP subjects (evenly distributed between clinical stages) and 50 controls were studied. Interleukin-6 (IL-6), interleukin-8 (IL-8), and soluble intercellular adhesion molecule 1 (sICAM-1) were significantly elevated in CP subjects compared to controls. The levels of IL-6 and IL-8 increased with advancing disease stages, with the highest levels observed in CP with diabetes and EPD (clinical stage 3). Furthermore, hepatocyte growth factor and macrophage-derived chemokine were significantly increased in clinical stage 3 compared to controls. Conclusion Our study reveals a progressive elevation in pro-inflammatory cytokines and chemokines with advancing clinical stages of CP. These findings indicate potential targets for the development of disease-modifying interventions.
Do GWAS-Identified Risk Variants for Chronic Lymphocytic Leukemia Influence Overall Patient Survival and Disease Progression?
Cabrera-Serrano, Antonio José , Sánchez‐Maldonado, José Manuel , Macauda, Angelica , García-Martín, Paloma, Benavente, Yolanda , Landi, Stefano , Clay‐Gilmour, Alyssa , Niazi, Yasmeen , Espinet, Blanca , Rodríguez‐Sevilla, Juan José , Pérez, Eva María, Maffei, Rossana , Blanco, Gonzalo , Giaccherini, Matteo , Marasca, Roberto , López‐Nevot, Miguel Ángel , Thomsen, Hauke , Gámez, Irene, Campa, Daniele , Moreno, Vı́ctor , Sanjosé, Sílvia de , Marcos‐Gragera, Rafael , García‐Álvarez, María , Dierssen‐Sotos, Trinidad , Jerez, Andrés , Butrym, Aleksandra , Hemminki, Kari , Li, Yang , Berndt, Sonja I. , Casabonne, Delphine , Alcoceba, Miguel , Puiggros, Anna , Netea, Mihai G. , Försti, Asta , Canzian, Federico , Sáinz, Juan , Benavente, Yolanda , Landi, Stefano , Espinet, Blanca , Rodríguez-Sevilla, Juan José , Maffei, Rossana , Blanco, Gonzalo , Giaccherini, Matteo , Marasca, Roberto , López-Nevot, Miguel Ángel , Thomsen, Hauke , Moreno, Victor , Marcos-Gragera, Rafael , Dierssen-Sotos, Trinidad , Jerez, Andrés , Butrym, Aleksandra , Hemminki, Kari , Li, Yang , Alcoceba, Miguel , Puiggros, Anna , Försti, Asta , Canzian, Federico , Sainz, Juan , Horst, Rob ter , García-Martín, Paloma, Cerhan, James R. , Chen-Liang, Tzu-Hua , Norman, Aaron D. , Luppi, Mario , Slager, Susan L. , Netea, M. G.

Mayo Clinic

International Journal of Molecular Sciences | April 28, 2023 | Volume: 24 | Issue: 9 | Pages: 8005

10.3390/ijms24098005 | PMID 37175717 Get It

Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults worldwide. Although genome-wide association studies (GWAS) have uncovered the germline genetic component underlying CLL susceptibility, the potential use of GWAS-identified risk variants to predict disease progression and patient survival remains unexplored. Here, we evaluated whether 41 GWAS-identified risk variants for CLL could influence overall survival (OS) and disease progression, defined as time to first treatment (TTFT) in a cohort of 1039 CLL cases ascertained through the CRuCIAL consortium. Although this is the largest study assessing the effect of GWAS-identified susceptibility variants for CLL on OS, we only found a weak association of ten single nucleotide polymorphisms (SNPs) with OS (p < 0.05) that did not remain significant after correction for multiple testing. In line with these results, polygenic risk scores (PRSs) built with these SNPs in the CRuCIAL cohort showed a modest association with OS and a low capacity to predict patient survival, with an area under the receiver operating characteristic curve (AUROC) of 0.57. Similarly, seven SNPs were associated with TTFT (p < 0.05); however, these did not reach the multiple testing significance threshold, and the meta-analysis with previous published data did not confirm any of the associations. As expected, PRSs built with these SNPs showed reduced accuracy in prediction of disease progression (AUROC = 0.62). These results suggest that susceptibility variants for CLL do not impact overall survival and disease progression in CLL patients.
A Reduced Pancreatic Polypeptide Response is Associated With New-onset Pancreatogenic Diabetes Versus Type 2 Diabetes
Hart, Phil A. , Kudva, Yogish C. , Yadav, Dhiraj , Andersen, Dana K. , Li, Yisheng , Toledo, Frederico G. S. , Wang, Fuchenchu , Cusi, Kenneth , Park, Walter G. , Saeed, Zeb , Considine, Robert V. , Graham, Sarah C., Rinaudo, Jo Ann, Goodarzi, Mark O. , Cusi, Kenneth , Bellin, Melena D. , Bradley, David , Brand, Randall E. , Fisher, William P. , Mather, Kieren J. , Serrano, José

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | November 21, 2022 | Volume: 108 | Issue: 5 | Pages: e120-e128

10.1210/clinem/dgac670 | PMID 36404274 Get It

Abstract Purpose Pancreatogenic diabetes refers to diabetes mellitus (DM) that develops in the setting of a disease of the exocrine pancreas, including pancreatic ductal adenocarcinoma (PDAC) and chronic pancreatitis (CP). We sought to evaluate whether a blunted nutrient response of pancreatic polypeptide (PP) can differentiate these DM subtypes from type 2 DM (T2DM). Methods Subjects with new-onset DM (&lt;3 years’ duration) in the setting of PDAC (PDAC-DM, n = 28), CP (CP-DM, n = 38), or T2DM (n = 99) completed a standardized mixed meal tolerance test, then serum PP concentrations were subsequently measured at a central laboratory. Two-way comparisons of PP concentrations between groups were performed using Wilcoxon rank-sum test and analysis of covariance while adjusting for age, sex, and body mass index. Results The fasting PP concentration was lower in both the PDAC-DM and CP-DM groups than in the T2DM group (P = 0.03 and &lt;0.01, respectively). The fold change in PP at 15 minutes following meal stimulation was significantly lower in the PDAC-DM (median, 1.869) and CP-DM (1.813) groups compared with T2DM (3.283; P &lt; 0.01 for both comparisons). The area under the curve of PP concentration was significantly lower in both the PDAC-DM and CP-DM groups than in T2DM regardless of the interval used for calculation and remained significant after adjustments. Conclusions Fasting PP concentrations and the response to meal stimulation are reduced in new-onset DM associated with PDAC or CP compared with T2DM. These findings support further investigations into the use of PP concentrations to characterize pancreatogenic DM and to understand the pathophysiological role in exocrine pancreatic diseases (NCT03460769).
Development of a Clinical Prediction Model for Diabetes in Chronic Pancreatitis: The PREDICT3c Study
Hart, Phil A. , Li, Liang , Yang, Yunlong, Chang, Eleanor, Bellin, Melena D. , Fisher, William E., Fogel, Evan L. , Forsmark, Christopher E., Park, Walter G. , Vege, Santhi Swaroop , Andersen, Dana K. , Conwell, Darwin L. , Yadav, Dhiraj , Goodarzi, Mark O. , Bellin, Melena D , Yadav, Dhiraj , Goodarzi, Mark O , Jeon, Christie Y. , Van Den Eeden, Stephen K , Serrano, José , Whitcomb, David C. , Conwell, Darwin L.

Mayo Clinic

Diabetes Care | November 16, 2022 | Volume: 46 | Issue: 1 | Pages: 46-55

10.2337/dc22-1414 | PMID 36382801 Get It

OBJECTIVE Diabetes that arises from chronic pancreatitis (CP) is associated with increased morbidity and mortality. Methods to predict which patients with CP are at greatest risk for diabetes are urgently needed. We aimed to examine independent risk factors for diabetes in a large cohort of patients with CP. RESEARCH DESIGN AND METHODS This cross-sectional study comprised 645 individuals with CP enrolled in the PROCEED study, of whom 276 had diabetes. We conducted univariable and multivariable regression analyses of potential risk factors for diabetes. Model performance was assessed by area under the receiver operating characteristic curve (AUROC) analysis, and accuracy was evaluated by cross validation. Exploratory analyses were stratified according to the timing of development of diabetes relative to the diagnosis of pancreatitis. RESULTS Independent correlates of diabetes in CP included risk factors for type 2 diabetes (older age, overweight/obese status, male sex, non-White race, tobacco use) as well as pancreatic disease–related factors (history of acute pancreatitis complications, nonalcoholic etiology of CP, exocrine pancreatic dysfunction, pancreatic calcification, pancreatic atrophy) (AUROC 0.745). Type 2 diabetes risk factors were predominant for diabetes occurring before pancreatitis, and pancreatic disease–related factors were predominant for diabetes occurring after pancreatitis. CONCLUSIONS Multiple factors are associated with diabetes in CP, including canonical risk factors for type 2 diabetes and features associated with pancreatitis severity. This study lays the groundwork for the future development of models integrating clinical and nonclinical data to identify patients with CP at risk for diabetes and identifies modifiable risk factors (obesity, smoking) on which to focus for diabetes prevention.
Rationale and Design for the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study
Hart, Phil A. , Park, Walter G. , Dyer, Anne‐Marie , Andersen, Dana K. , Buxbaum, James , Conwell, Darwin L. , Dungan, Kathleen , Easler, Jeffrey J. , Fogel, Evan L. , Greenbaum, Carla J. , Kalyani, Rita R. , Korc, Murray , Kozarek, Richard A. , Laughlin, Maren R. , Lee, Peter J. , Maranki, Jennifer , Speake, Cate, Toledo, Frederico G. S. , Trikudanathan, Guru , Vege, Santhi Swaroop , Yazıcı, Cemal , Zaheer, Atif , Forsmark, Christopher E., Yadav, Dhiraj , Papachristou, Georgios I. , Chinchilli, Vernon M , Afghani, Elham , Akshintala, Venkata S. , Pandol, Stephen J. , Phillips, Anna Evans , Serrano, José , Singh, Vikesh K. , Speake, Cate , Tirkes, Temel , Wang, Ming , Bellin, Melena D.

Mayo Clinic

Pancreas | October 7, 2022 | Volume: 51 | Issue: 6 | Pages: 568-574

10.1097/mpa.0000000000002079 | PMID 36206460 Get It

Abstract Acute pancreatitis (AP) is a disease characterized by an acute inflammatory phase followed by a convalescent phase. Diabetes mellitus (DM) was historically felt to be a transient phenomenon related to acute inflammation; however, it is increasingly recognized as an important late and chronic complication. There are several challenges that have prevented precisely determining the incidence rate of DM after AP and understanding the underlying mechanisms. The DREAM (Diabetes RElated to Acute Pancreatitis and its Mechanisms) Study is a prospective cohort study designed to address these and other knowledge gaps to provide the evidence needed to screen for, prevent, and treat DM after AP. In the following article, we summarize literature regarding the epidemiology of DM after AP and provide the rationale and an overview of the DREAM study.
Characterizing mechanism-based pain phenotypes in patients with chronic pancreatitis: a cross-sectional analysis of the PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies
Saloman, Jami L. , Conwell, Darwin L. , Fogel, Evan L. , Vege, Santhi Swaroop , Li, Liang , Andersen, Dana K. , Fisher, William E., Forsmark, Christopher E., Hart, Phil A. , Park, Walter G. , Topazian, Mark , Yadav, Dhiraj , Saloman, Jami L , Li, Shuang , Pandol, Stephen J. , Phillips, Anna Evans , Van Den Eeden, Stephen K , Serrano, José

Mayo Clinic

Pain | June 8, 2022 | Volume: 164 | Issue: 2 | Pages: 375-384

10.1097/j.pain.0000000000002710 | PMID 36149018 Get It

Abstract Pain is common in chronic pancreatitis (CP) and profoundly reduces quality of life (QoL). Multiple underlying mechanisms contribute to a heterogenous pain experience and reduce efficacy of pain management. This study was designed to characterize the distribution of mechanism-based pain phenotypes in painful CP. The data analyzed were collected as part of the PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies, an NCI/NIDDK-funded longitudinal study of the natural history of CP. The PROspective Evaluation of Chronic pancreatitis for EpidEmiologic and translational stuDies includes patient-reported outcome (PRO) measures of pain, medication use, global health, and QoL. Of subjects (N = 681) with CP, 80% experienced abdominal pain within the year before enrollment. Subjects who experienced pain in the week before enrollment (N = 391) completed PROMIS Neuropathic and Nociceptive Pain Quality instruments which were then used to classify them by pain type: 40% had nociceptive, 5% had neuropathic-like, and 32% had both types of pain. The prevalence of having both types of pain was higher among women and subjects with diabetes mellitus, whereas nociceptive-only pain was more prevalent among men and those with pancreatic duct stricture. Other factors, including pain medication use and healthcare utilization, did not differ between groups based on pain type. Subjects in the Both group had significantly worse health and QoL scores relative to those with nociceptive-only pain, suggesting that using psychosocial pain surveys may be useful for understanding pain subtypes in patients with CP. Additional research is needed to identify biochemical and biophysical signatures that may associate with and predict responses to mechanism-specific interventions.
Standard Operating Procedures for Biospecimen Collection, Processing, and Storage
Fisher, William E., Cruz‐Monserrate, Zobeida , McElhany, Amy L., Hart, Phil A. , Ghosh, Ria , Buren, George Van , Fishman, Douglas S., Rinaudo, Jo Ann, Serrano, José , Srivastava, Sudhir , Mace, Thomas A. , Topazian, Mark , Feng, Ziding , Yadav, Dhiraj , Hughes, Steven J. , Liu, Robert Y., Lu, Emily Y., Orr, Robert Scott, Abouhamze, Amer, Troendle, David M. , Uç, Aliye , Lowe, Mark E. , Conwell, Darwin L. , Whitcomb, David C. , Serrano, Jose , Lesinski, Gregory B , Ghosh, Ria, Pandol, Stephen J. , Orr, Robert, Steen, Hanno , Sellers, Zachary M.

Mayo Clinic

Pancreas | October 16, 2018 | Volume: 47 | Issue: 10 | Pages: 1213-1221

10.1097/mpa.0000000000001171 | PMID 30325860 Get It

Abstract High-quality and well-annotated biorepositories are needed to better understand the pathophysiology and biologic mechanisms of chronic pancreatitis (CP) and its consequences. We report a methodology for the development of a robust standard operating procedure (SOP) for a biorepository based on the experience of the clinical centers within the consortium to study Chronic Pancreatitis, Diabetes and Pancreas Cancer Clinical Centers (CPDPC), supported by the National Cancer Institute and the National Institute for Diabetes and Digestive and Kidney Diseases as a unique multidisciplinary model to study CP, diabetes, and pancreatic cancer in both children and adults. Standard operating procedures from the CPDPC centers were evaluated and consolidated. The literature was reviewed for standard biorepository operating procedures that facilitated downstream molecular analysis. The existing literature on biobanking practices was harmonized with the SOPs from the clinical centers to produce a biorepository for pancreatic research. This article reports the methods and basic principles behind the creation of SOPs to develop a biorepository for the CPDPC. These will serve as a guide for investigators developing biorepositories in pancreas research. Rigorous and meticulous adherence to standardized biospecimen collection will facilitate investigations to better understand the pathophysiology and biologic mechanisms of CP, diabetes, and pancreatic cancer.
PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies
Yadav, Dhiraj , Park, Walter G. , Fogel, Evan L. , Li, Liang , Chari, Suresh T. , Feng, Ziding , Fisher, William E., Forsmark, Christopher E., Habtezion, Aida , Hart, Phil A. , Hughes, Steven J. , Othman, Mohamed O. , Rinaudo, Jo Ann, Serrano, José , Srivastava, Sudhir , Topazian, Mark , Conwell, Darwin L. , Serrano, Jose , Jeon, Christie Y. , Pandol, Stephen J. , Tirkes, Temel , Van Den Eeden, Stephen K , Whitcomb, David C. , Chari, Suresh T

Mayo Clinic

Pancreas | October 16, 2018 | Volume: 47 | Issue: 10 | Pages: 1229-1238

10.1097/mpa.0000000000001170 | PMID 30325862 Get It

Abstract Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) is the first prospective, observational cohort study of chronic pancreatitis (CP) in the United States. The primary goals of PROCEED are to define disease progression, test the predictive capability of candidate biomarkers, and develop a platform to conduct translational and mechanistic studies in CP. Using objective and consensus-driven criteria, PROCEED will enroll adults at different stages of CP—controls, suspected CP, and definite CP. In addition to collecting detailed information using structured case report forms and protocol-mandated evaluations at baseline and during follow-up, PROCEED will establish a linked biorepository of blood, urine, saliva, stool, pancreatic fluid, and pancreatic tissue. Enrollment for PROCEED began in June 2017. As of July 1, 2018, nine clinical centers of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer are enrolling, and 350 subjects have completed baseline evaluation. In conclusion, PROCEED will provide the most accurate and reliable estimates to date on progression of CP. The established cohort and biorepository will facilitate numerous analyses, leading to new strategies for diagnosis, methods to monitor disease progression, and treatment of CP.